Prescription for CGM 2026: Do You Need One?

Introduction

If you're considering a continuous glucose monitor for 2026, the prescription question matters for two reasons: access and cost. In the United States, prescription CGMs require a doctor's prescription to purchase and to qualify for insurance reimbursement. This means the path to a CGM typically runs through your healthcare provider, even if you're prepared to pay out of pocket.

The prescription requirement isn't arbitrary. It reflects how the FDA has classified these devices and how insurance companies structure their coverage policies. To qualify for insurance coverage, you may need a medical device prescription from your health care provider, along with documentation that you meet specific clinical criteria—often related to diabetes type, insulin use, or hypoglycemia risk.

But the CGM landscape is changing. New device categories, evolving FDA guidance, and shifts in how people manage glucose are all reshaping what "prescription for CGM 2026" will mean in practice. Some monitoring technologies are exploring different regulatory pathways, while traditional CGM manufacturers are expanding their product lines to reach broader audiences. Understanding where the requirements stand today—and where they're headed—helps you navigate your options, whether you're newly diagnosed, managing long-standing diabetes, or supporting someone who is. For context on related monitoring technologies, see our guide on smartwatch measure blood sugar: can it really work?

This article walks through the current prescription landscape, what determines whether you need one, and what alternatives exist as we move into 2026.

Understanding CGMs

A continuous glucose monitor (CGM) is a wearable device that tracks glucose levels in real time throughout the day and night. Unlike traditional fingerstick blood glucose meters that provide a single snapshot, a CGM uses a small sensor inserted under the skin to measure glucose in interstitial fluid — the liquid surrounding your cells. The sensor sends readings to a receiver or smartphone app every few minutes, creating a continuous trace that shows not just where your glucose is now, but where it's heading and how fast.

CGMs are used primarily by people with diabetes to guide daily treatment decisions, spot patterns, and reduce the risk of dangerous highs and lows. They're particularly valuable for anyone using insulin, where timing and dosing depend on knowing glucose trends in addition to current levels. Many users also find CGMs helpful for understanding how food, activity, stress, and sleep affect their glucose — information that's invisible with periodic fingersticks alone.

Types of CGMs: Adjunctive vs. Non-Adjunctive

CGMs fall into two regulatory categories that determine how they can be used. Adjunctive CGMs require you to confirm the reading with a traditional blood glucose meter (BGM) before making any treatment decision — such as taking insulin or treating a low. These devices provide trend data and alerts, but they are not approved as the sole basis for dosing. Non-adjunctive CGMs, by contrast, are approved for direct treatment decisions without fingerstick confirmation. The distinction matters for insurance coverage, Medicare reimbursement, and which device your care team may recommend.

Most current-generation CGMs from major manufacturers are non-adjunctive, meaning they can replace routine fingersticks for dosing decisions. Older models and some budget-tier sensors may still carry the adjunctive designation. Understanding the difference helps you know what your device is cleared to do — and what your insurance or Medicare plan will cover under its CGM benefit.

Who Uses a CGM?

CGMs are most commonly prescribed for people with type 1 diabetes and people with type 2 diabetes who use insulin. However, use is expanding: some endocrinologists prescribe CGMs for patients on non-insulin medications to help with pattern recognition and behavior change, and some people without diabetes use CGMs off-label for wellness tracking (though insurance typically does not cover non-diabetes use). Coverage criteria vary by payer, and many plans require documentation that you meet specific clinical thresholds — such as multiple daily insulin injections or a history of hypoglycemia — before approving a CGM.

If you're exploring whether a CGM might be right for you, the first step is a conversation with your care team about your glucose management goals and whether your insurance or Medicare plan covers the device. For context on related monitoring technologies, see Smartwatch Measure Blood Sugar: Can It Really Work? to understand what consumer wearables can and cannot do compared to FDA-cleared CGMs.

Current Prescription Requirements

In the United States, prescription CGMs require a doctor's prescription to purchase and to qualify for insurance reimbursement. This requirement applies across Medicare, Medicaid, and private insurance plans. The treating practitioner must provide a prescription, and the CGM must be prescribed under its FDA indications for use.

Who Qualifies for a Prescription CGM

To be eligible for coverage of a CGM, the patient must have diabetes, and the device must be prescribed by a healthcare provider. CGMs are considered medically necessary for individuals diagnosed with diabetes who require insulin injections or an insulin pump, especially when they experience inadequate glycemic control or hypoglycemia.

Insurance coverage typically requires documentation that the CGM is medically necessary. This means your care team must show that continuous monitoring addresses a specific clinical need — such as frequent low blood sugar episodes, difficulty maintaining target glucose levels, or the need for intensive insulin management.

The Prescription Process

Obtaining a CGM prescription typically involves a visit with your primary care provider or endocrinologist. The provider will assess your diabetes management needs, review your current glucose monitoring routine, and determine whether a CGM is appropriate for your situation. They will then write a prescription that specifies the device model and necessary supplies.

To qualify for insurance coverage, you may need a medical device prescription from your healthcare provider that includes specific details about your diagnosis, current treatment regimen, and the clinical rationale for continuous monitoring. Some plans require prior authorization before approving coverage.

Prescription Requirements Across Payers

Medicare, Medicaid, and private insurers all maintain their own criteria for CGM coverage, but the prescription requirement is universal. Medicare requires that the CGM be prescribed under its FDA indications and that the patient have diabetes. Private insurers may add additional criteria, such as requiring a minimum number of daily blood glucose checks or documented episodes of hypoglycemia.

For those interested in alternatives, over-the-counter options exist in other product categories, but prescription CGMs remain the standard for insurance-covered continuous glucose monitoring.

Future Trends in CGM Accessibility

The landscape for continuous glucose monitor access is shifting. The American Diabetes Association's 2026 Standards of Care mark a significant departure from previous guidance, expanding who should be offered CGM and reducing the administrative barriers that have historically limited access.

Broader Clinical Recommendations

The ADA 2026 Standards now recommend CGM use at diabetes onset and anytime thereafter for adults on insulin therapy and those on noninsulin therapies that can cause hypoglycemia. This represents a widening of the clinical window — CGM is no longer positioned primarily as a tool for insulin users alone.

For the first time, the recommendations advocate CGM use for adults with type 2 diabetes, even for those on glucose-lowering therapies other than insulin. This shift acknowledges that real-time glucose data benefits a much larger population than the traditional prescription criteria allowed. The guidance does not eliminate the prescription requirement itself, but it does redefine who should be considered eligible.

Reduced Administrative Barriers

New recommendations state there should be no requirement for C-peptide level or presence of islet autoantibodies before initiating advanced diabetes technology. These lab tests have historically been used by insurers and some clinicians as gatekeeping criteria — proof that a patient's pancreas function justifies the device. Removing this barrier from the clinical standard may reduce the documentation burden required to obtain a prescription and subsequent insurance approval.

This does not mean prescriptions will disappear in 2026, but it does mean the pathway to obtaining one may become more straightforward. Clinicians who follow the ADA Standards will have explicit guidance supporting CGM prescription without requiring additional diagnostic testing that delays access.

What This Means for Prescription Requirements

The ADA Standards do not regulate the FDA classification of devices or change federal prescription requirements. A device that requires a prescription today will still require one in 2026 unless the manufacturer pursues and receives FDA clearance for over-the-counter status. What the Standards do influence is clinical practice — who gets prescribed a CGM, under what circumstances, and with what documentation.

If insurers and care teams adopt the 2026 Standards widely, more people with type 2 diabetes who are not on insulin may receive prescriptions. This expands the eligible population without changing the legal requirement for a prescription itself. For readers exploring over-the-counter GLP-1 options or other accessible diabetes tools, the distinction matters: expanded prescription eligibility is not the same as over-the-counter availability.

The trend is toward broader access within the prescription framework, not necessarily around it. Whether additional CGM models will seek OTC clearance by 2026 remains a manufacturer and regulatory decision, separate from the ADA's clinical guidance.

Alternatives to Prescription CGMs

Not everyone who wants to monitor glucose needs a prescription CGM. For many people with type 2 diabetes who are not on insulin, traditional blood glucose meters remain the practical choice. These devices require a finger prick and measure glucose at a single moment, rather than continuously. They cost significantly less — typically $15–$40 for the meter itself, compared to $100–$400 per month for CGM supplies without insurance coverage.

When a Traditional Meter Is Enough

If you manage type 2 diabetes with lifestyle changes, metformin, or other non-insulin medications, your care team may recommend checking glucose a few times per week or before and after meals during adjustments. A traditional meter handles this well. The upfront cost is low, test strips are widely available, and most insurance plans cover them with minimal copay. For someone whose glucose stays relatively stable, the continuous data from a CGM may not change day-to-day decisions enough to justify the expense.

Weighing Cost Against Information

CGMs offer real-time trends, alerts for highs and lows, and a detailed picture of how food, activity, and sleep affect glucose. That information can be valuable for anyone learning to manage diabetes or troubleshooting unexplained patterns. But the monthly cost adds up quickly without insurance support. Before committing to a CGM, compare what you will learn from continuous data against what you already know from periodic checks. If your glucose is predictable and your current regimen is working, a meter may be all you need. If you are adjusting medications, starting a new exercise routine, or experiencing unexplained swings, the additional data from a CGM can guide faster, more confident decisions — but confirm the cost and coverage details with your insurer first.

For those exploring whether over-the-counter GLP-1 options are real or effective, the same cost-versus-benefit reasoning applies: prioritize proven tools and discuss alternatives with your care team before adding unregulated products to your routine.

Choosing the Right Device for Your Situation

Start by asking your care team what monitoring frequency they recommend. If the answer is "check fasting glucose twice a week," a traditional meter will do the job. If the recommendation is "track trends around meals and overnight," a CGM may be worth the cost. Insurance coverage often follows the same logic: plans typically cover CGMs for insulin users and may require prior authorization or deny coverage for others. Check your plan's durable medical equipment policy and ask whether a letter of medical necessity from your provider would help. If cost is the main barrier and your clinical picture supports continuous monitoring, some manufacturers offer patient-assistance programs or lower-cost cash-pay options — but these are not advertised widely, so call the manufacturer directly to ask.

Conclusion

The landscape of CGM access is shifting, but as of 2026, most continuous glucose monitors still require a prescription. The FDA's approval of over-the-counter options like the Dexcom Stelo and Abbott Lingo signals a growing recognition that glucose monitoring can benefit people beyond those on intensive insulin therapy, but prescription devices remain the standard for comprehensive diabetes management and insurance coverage.

If you use insulin three or more times daily or experience frequent low blood sugars, your insurance plan will likely cover a prescription CGM, making that path both clinically appropriate and financially practical. For those managing type 2 diabetes without insulin, prediabetes, or general metabolic awareness, the newer OTC options provide a legitimate entry point — though without the real-time alarms, integration with insulin pumps, or coverage that prescription systems offer.

The question isn't just whether you need a prescription for a CGM in 2026; it's which pathway fits your medical situation, your budget, and your monitoring goals. Start the conversation with your care team. They can assess whether a prescription device is indicated, walk you through insurance requirements, and help you weigh the trade-offs if you're considering an over-the-counter alternative. As regulatory frameworks continue to evolve, access will likely expand further — but the clinical guidance and coverage infrastructure still favor the prescription route for most people living with diabetes.

For those exploring alternatives to prescription medications alongside glucose monitoring, understanding the full range of management tools can be helpful. See Is Over-the-Counter GLP-1 Real? GLP-1 Gummies Explained for context on another emerging category of diabetes-related products and what the evidence actually supports.

Explore whether you will need a prescription for a CGM in 2026 and learn about current trends and regulations.